Company intelligence / Profile preview
GeNeuro
Geneva, Geneva, Switzerlandgeneuro.ch ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Temelimab, their lead monoclonal antibody targeting HERV-W Env, showed coherent impact across key markers associated with disease progression in a 200-patient 2-year study in MS. In March 2022, the ProTEct-MS study confirmed excellent safety profile and tolerability for higher doses, though investor response was negative with share price dropping over 10%[2][5]
- Therapeutic areas
- ImmunologyNeurologyInfectious DiseasesEndocrinology
- Modalities
- Monoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on GeNeuro.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GeNeuro.